Summit Therapeutics Inc. (SMMT) Operating cash flow 2017–2025
Summit Therapeutics Inc. (SMMT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$322.9MFY2025 · since FY2017: -$21.5M → -$322.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$322.9M | -127.2% |
| FY2024 | -$142.1M | -85.1% |
| FY2023 | -$76.8M | -84.6% |
| FY2022 | -$41.6M | +42.7% |
| FY2021 | -$72.6M | -50.9% |
| FY2020 | -$48.1M | — |
| FY2018 | -$35.1M | -63.3% |
| FY2017 | -$21.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SMMT financial trends
SMMT RevenueSMMT Net incomeSMMT Net marginSMMT Gross profitSMMT Gross marginSMMT Operating incomeSMMT Operating marginSMMT Free cash flowSMMT Capital expendituresSMMT Return on equitySMMT Stock buybacksSMMT Dividends paidSMMT Total assetsSMMT Total liabilitiesSMMT Shareholders’ equitySMMT overview →